Evidence map›Paper›PMID 36615411›Full record

ArticleMolecules (Basel, Switzerland)2022

Traditional Machine and Deep Learning for Predicting Toxicity Endpoints.

Ulf Norinder

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Transforming Molecular Synthesis With Large Language Models.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ulf NorinderDepartment of Computer and Systems Sciences, Stockholm University, 164 07 Kista, Sweden.

Funding

Swedish Foundation for Strategic Environmental Research 2018/11
6 · The paper itself

Abstract

Molecular structure property modeling is an increasingly important tool for predicting compounds with desired properties due to the expensive and resource-intensive nature and the problem of toxicity-related attrition in late phases during drug discovery and development. Lately, the interest for applying deep learning techniques has increased considerably. This investigation compares the traditional physico-chemical descriptor and machine learning-based approaches through autoencoder generated descriptors to two different descriptor-free, Simplified Molecular Input Line Entry System (SMILES) based, deep learning architectures of Bidirectional Encoder Representations from Transformers (BERT) type using the Mondrian aggregated conformal prediction method as overarching framework. The results show for the binary CATMoS non-toxic and very-toxic datasets that for the former, almost equally balanced, dataset all methods perform equally well while for the latter dataset, with an 11-fold difference between the two classes, the MolBERT model based on a large pre-trained network performs somewhat better compared to the rest with high efficiency for both classes (0.93-0.94) as well as high values for sensitivity, specificity and balanced accuracy (0.86-0.87). The descriptor-free, SMILES-based, deep learning BERT architectures seem capable of producing well-balanced predictive models with defined applicability domains. This work also demonstrates that the class imbalance problem is gracefully handled through the use of Mondrian conformal prediction without the use of over- and/or under-sampling, weighting of classes or cost-sensitive methods.

Indexed as

Deep LearningDrug DiscoveryMachine LearningMolecular StructureBERTCATMoS datasetCDDDconformal predictionrandom forestRDKit

Identifiers

PMID36615411
PMCPMC9822478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.